Search
What are you looking for?
Start main content

Press Releases

Press Releases

https://www.med.cuhk.edu.hk/press-releases/cuhk-discovers-innovative-flow-diverters-pipeline-as-effective-treatment-for-cerebral-aneurysms-in-asias-first-clinical-study-in-collaboration-with-seven-medical-centres
https://www.med.cuhk.edu.hk/press-releases/cuhk-discovers-innovative-flow-diverters-pipeline-as-effective-treatment-for-cerebral-aneurysms-in-asias-first-clinical-study-in-collaboration-with-seven-medical-centres

CUHK Discovers Innovative ‘Flow Diverters’ (Pipeline) as Effective Treatment for Cerebral Aneurysms in Asia’s First Clinical Study in Collaboration with Seven Medical Centres

The Vascular and Interventional Radiology Foundation Clinical Science Centre (Centre) at The Chinese University of Hong Kong (CUHK) has successfully conducted an Asia’s first clinical research with seven medical centres in Hong Kong on the use of ‘Flow Diverters’ (Pipeline) in treating cerebral aneurysms. Under the leadership of Professor Simon Chun Ho Yu, Centre’s director and professor at Department of Imaging and Interventional Radiology at CUHK, the study discovered that ‘Flow Diverter’ (Pipeline) is a safe and effective approach to treat cerebral aneurysms. Cerebral aneurysm is a potential health hazard that occurs in about 2 to 6% of the population in Hong Kong. The etiology is thought to be associated with hypertension, atherosclerosis, and congenital factors leading to vessel wall weakening.

 

Flow diverter (Pipeline) (net in silver color)

Flow diverter (Pipeline) (net in silver color).

Aneurysm rupture is a cause of intracranial bleeding that may lead to severe disability and the death rate is as high as 45%. The risk of rupture of an aneurysm is about 1.3% per year. In the overall population, the incidence rate of aneurysm rupture is 10.5 per 100,000 people. Conventionally, cerebral aneurysms are treated with open surgery using clipping but it is perceived as invasive with risk. Endovascular coil embolization is a less invasive approach but its feasibility is limited by the fusiform morphology of the aneurysm. For large-sized aneurysms that have incorporated the parent vessel or aneurysms with wide neck, stent assisted coiling is necessary to retain the coils within the aneurysm sac so as not to interrupt the flow of the parent artery. Recurrence rates of aneurysms after treatment are as high as 17% for coil embolization and 15% for stent-assisted coiling.

The use of ‘flow diverters’ (Pipeline) is a technological breakthrough in the treatment of cerebral aneurysms. A flow diverter is a tube-like device composed of tightly knitted fine metal strips, to be implanted in the vascular segment affected by the aneurysm using percutaneous endovascular approach. After placement of flow diverters, blood flow is diverted away from the aneurysm so that the aneurysm eventually regresses. The treatment is not limited by the size or morphology of the aneurysm, and it does not affect blood vessels adjacent to the aneurysm.

 

Professor Simon Chun Ho YU, Professor, Department of Imaging and Interventional Radiology and Director of Vascular and Interventional Radiology Foundation Clinical Science Centre, CUHK present the Asia's first clinical study in collaboration with seven medical centres on the innovative flow diverters (Pipeline) for treating cerebral aneurysms

Professor Simon Chun Ho YU, Professor, Department of Imaging and Interventional Radiology and Director of Vascular and Interventional Radiology Foundation Clinical Science Centre, CUHK present the Asia's first clinical study in collaboration with seven medical centres on the innovative flow diverters (Pipeline) for treating cerebral aneurysms.

The clinical study was conducted from September 2008 to September 2011, involving 143 patients and 178 aneurysms. In this study, the flow diverter (Pipeline) was found to be a safe and effective treatment for aneurysms with unfavorable morphological features such as wide neck, large size, fusiform morphology, incorporation of side branches, and post-treatment recanalization. The study included 36 male and 107 female patients, of mean age 54.9 years. Cases studied included: (1) saccular or fusiform intracranial aneurysms, (2) untreated unruptured aneurysms or recurrent aneurysms following previous treatment, and (3) parent vessel of diameter 2.5-5.0mm distal or proximal to the target aneurysm. Thirty-four of all 178 aneurysms (19.1%) had been treated previously. The procedure was successfully accomplished in all aneurysms (100%). For most of the cases (81.5%), only one ‘flow diverter’ (Pipeline) was placed in each aneurysm. Patients were followed-up after the treatment for an average of 17.6 months (ranged from 3 to 39.2 months), complete occlusion was found in 55.7% of aneurysms at 6 months, 81.3% of aneurysms at 12 months, and 84.5% of aneurysms at 18 months. The peri-procedure death or major stroke rate was 3.5%. All parent arteries remained patent without occlusion in all 178 aneurysms during the follow-up period. Mild parent artery stenosis (to a degree of 20% to 30%) and occlusion of arterial side branches respectively occurred in 1.4% of the cases, without clinical consequence.

CUHK recommends ‘flow diverters’ (Pipeline) as a preferred treatment for unruptured aneurysms and recurrent aneurysms. The results of the study were published in the authoritative journal Radiology in December 2012.

 

Professor Simon Chun Ho YU and representatives from other medical centres

Professor Simon Chun Ho YU and representatives from other medical centres.

Medical centers and doctors participating in the study:
  • Prince of Wales Hospital: Department of Imaging and Interventional Radiology (Simon Chun Ho YU, Joyce Wai Yi HUI); Division of Neurosurgery, Department of Surgery (George Kwok Chu WONG); The Chinese University of Hong Kong
  • Kwong Wah Hospital: Department of Neurosurgery (John Ching Kwong KWOK, Kwong Yau CHAN); Department of Radiology (Samuel Shun LAU)
  • St. Theresa Hospital: Scanning Department (Pui Wai CHENG).
  • Queen Mary Hospital: Department of Neurosurgery (Matthew Wai Man LUI, Ka Ming LEUNG); Department of Radiology (Raymand Lee)
  • Queen Elizabeth Hospital: Department of Neurosurgery (Harold Kin Ming Cheng); Department of Radiology and Imaging (Yuk Ling CHEUNG, Chi Ming CHAN)
  • Tuen Mun Hospital: Department of Radiology, (Yui Chung Wong, Chong Boon TAN, Wai Lun POON).
  • Pamela Youde Nethersole Eastern Hospital: Neurosurgical Unit, Department of Surgery (Kai Yuen PANG, Alain Kai Sing WONG); Department of Radiology (Kai Hung FUNG);

More Press Releases

CUHK Study Proves Ablative Chemoembolization Doubles the Progression-Free Survival for Liver Cancer Patients

CUHK Study Proves Ablative Chemoembolization Doubles the Progression-Free Survival for Liver Cancer Patients

Research
CUHK Proves Prostate Artery Embolization Effective for Benign Prostatic Hyperplasia

CUHK Proves Prostate Artery Embolization Effective for Benign Prostatic Hyperplasia

Research
CUHK’s New Prostatic Artery Embolization Shows 90% Success Rate in Relieving Symptoms of Benign Prostatic Hyperplasia

CUHK’s New Prostatic Artery Embolization Shows 90% Success Rate in Relieving Symptoms of Benign Prostatic Hyperplasia

Clinical service
CUHK Succeeded in Animal Study and Clinical Case of Percutaneous Nanoknife New Breakthrough in Cancer Treatment

CUHK Succeeded in Animal Study and Clinical Case of Percutaneous Nanoknife New Breakthrough in Cancer Treatment

Research
CUHK Proves Modified HIFU Treatment Effective for Treating Uterine Fibroids

CUHK Proves Modified HIFU Treatment Effective for Treating Uterine Fibroids

Research
Insights into B-cells and GPR18 Gene Expression by CU Medicine team  Improve Prediction of Survival in Multiple Cancer Types

Insights into B-cells and GPR18 Gene Expression by CU Medicine team Improve Prediction of Survival in Multiple Cancer Types

Research
CU Medicine Team Discovers a Novel Prognostic Biomarker for a Doubled Survival in Head and Neck Cancer

CU Medicine Team Discovers a Novel Prognostic Biomarker for a Doubled Survival in Head and Neck Cancer

Research
CUHK in collaboration with West China School of Medicine co-Led World’s First-in-human Clinical Trial using CRISPR technology for lung cancer Confirmed gene-edited T-Cell Therapy is Safe and Feasible in Treatment of Advanced NSCLC

CUHK in collaboration with West China School of Medicine co-Led World’s First-in-human Clinical Trial using CRISPR technology for lung cancer Confirmed gene-edited T-Cell Therapy is Safe and Feasible in Treatment of Advanced NSCLC

Research
CUHK to Commence the Next-Generation Clinical Trials of CAR-T Cell Therapy for Haematological Malignancy

CUHK to Commence the Next-Generation Clinical Trials of CAR-T Cell Therapy for Haematological Malignancy

Research
CUHK Successfully Conducts Asia-Pacific’s First Hybrid Operating Room Non-invasive Bronchoscopic Microwave Ablation to Treat Lung Cancer

CUHK Successfully Conducts Asia-Pacific’s First Hybrid Operating Room Non-invasive Bronchoscopic Microwave Ablation to Treat Lung Cancer

Surgical advancement
李嘉誠基金會啟動《愛能助》兒童癌症項目 資助兒童罕見癌症 (Chinese version only)

李嘉誠基金會啟動《愛能助》兒童癌症項目 資助兒童罕見癌症 (Chinese version only)

Donation
Professor Tony MOK Honoured with the ESMO Lifetime Achievement Award Recognising His Global Leadership in Defining Lung Cancer Treatment Standard

Professor Tony MOK Honoured with the ESMO Lifetime Achievement Award Recognising His Global Leadership in Defining Lung Cancer Treatment Standard

Awards and honors
CUHK Receives an International Cancer Care Team Award Nominated by Patients

CUHK Receives an International Cancer Care Team Award Nominated by Patients

Awards and honors
CUHK Launches Multi-Cancer Prevention Programme Providing Free Screening to 10,000 HK Residents to Study Links with Obesity

CUHK Launches Multi-Cancer Prevention Programme Providing Free Screening to 10,000 HK Residents to Study Links with Obesity

Health Campaign
CUHK-led Global Study Sees Improvement in Overall Survival in Patients with Advanced Lung Cancer

CUHK-led Global Study Sees Improvement in Overall Survival in Patients with Advanced Lung Cancer

Research
CUHK Study Sees Increasing Global Incidence of Colorectal Cancer Among Younger People

CUHK Study Sees Increasing Global Incidence of Colorectal Cancer Among Younger People

Research
CUHK Pioneers Early Lung Cancer Treatment with Hybrid Operating Room Image Guided Electromagnetic Navigation Bronchoscopy

CUHK Pioneers Early Lung Cancer Treatment with Hybrid Operating Room Image Guided Electromagnetic Navigation Bronchoscopy

Surgical advancement
A CUHK-led International Study Demonstrates Immune-checkpoint Inhibitor Is Effective in Patients with Advanced Nasopharyngeal Cancer

A CUHK-led International Study Demonstrates Immune-checkpoint Inhibitor Is Effective in Patients with Advanced Nasopharyngeal Cancer

Research
CUHK Research Receives Recognitions by Top Medical Journals

CUHK Research Receives Recognitions by Top Medical Journals

Awards and honors
CUHK-HKU Study on Multi-gene Mutation-Drug Matching for Recurrent Ovarian Cancer Patients Providing Free Pharmacogenomic Analysis for 100 Patients in Hong Kong

CUHK-HKU Study on Multi-gene Mutation-Drug Matching for Recurrent Ovarian Cancer Patients Providing Free Pharmacogenomic Analysis for 100 Patients in Hong Kong

Research
CUHK Completes a 20,000-person Plasma DNA Screening Study of Nasopharyngeal Cancer, and Finds a Dramatic Shift to Early Stage Cancers

CUHK Completes a 20,000-person Plasma DNA Screening Study of Nasopharyngeal Cancer, and Finds a Dramatic Shift to Early Stage Cancers

Research
CUHK-led Research Confirms Novel Targeted Therapy Doubles the Effectiveness of Current Standard Treatment for ALK-Positive Lung Cancer

CUHK-led Research Confirms Novel Targeted Therapy Doubles the Effectiveness of Current Standard Treatment for ALK-Positive Lung Cancer

Research
CUHK Uncovers Novel Immune Escape Mechanism of Cancer Opening Up New Direction for Cancer Immunotherapy

CUHK Uncovers Novel Immune Escape Mechanism of Cancer Opening Up New Direction for Cancer Immunotherapy

Research
CUHK Unravels the Whole Genome of Nasopharyngeal Cancer A Great Leap Forward in Personalized Medicine Development

CUHK Unravels the Whole Genome of Nasopharyngeal Cancer A Great Leap Forward in Personalized Medicine Development

Research

Our Expert List

Many experts under the Faculty of Medicine are available for media interview.
Please click here for the expert list or contact us.